Connor, Clark & Lunn Investment Management (CC&L)
DRNA

Connor, Clark & Lunn Investment Management (CC&L)’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-167,538
Closed -$3.38M – 1259
2021
Q3 		$3.38M Buy
167,538
+79,527
+90% +$2.2M 0.02% 417
2021
Q2 		$3.29M Sell
88,011
-147,873
-63% -$4.53M 0.02% 443
2021
Q1 		$6.03M Sell
235,884
-64,017
-21% -$1.64M 0.03% 321
2020
Q4 		$6.61M Buy
299,901
+1,930
+0.6% +$42.5K 0.04% 283
2020
Q3 		$5.36M Buy
297,971
+25,585
+9% +$530K 0.04% 289
2020
Q2 		$6.92M Sell
272,386
-22,789
-8% -$491K 0.05% 251
2020
Q1 		$5.42M Buy
295,175
+109,325
+59% +$2.12M 0.05% 232
2019
Q4 		$4.09M Buy
+185,850
New +$3.74M 0.03% 301
2017
Q4 		– Sell
-68,975
Closed -$397K – 885
2017
Q3 		$397K Sell
68,975
-10,300
-13% -$37.5K ﹤0.01% 664
2017
Q2 		$251K Buy
79,275
+17,575
+28% +$55.5K ﹤0.01% 705
2017
Q1 		$210K Buy
61,700
+15,600
+34% +$43.9K ﹤0.01% 794
2016
Q4 		$133K Buy
46,100
+20,200
+78% +$71.8K ﹤0.01% 821
2016
Q3 		$152K Buy
25,900
+5,500
+27% +$19.3K ﹤0.01% 755
2016
Q2 		$61K Sell
20,400
-7,700
-27% -$31.6K ﹤0.01% 825
2016
Q1 		$151K Sell
28,100
-400
-1% -$2.52K ﹤0.01% 740
2015
Q4 		$338K Buy
28,500
+5,600
+24% +$64.1K ﹤0.01% 608
2015
Q3 		$188K Buy
22,900
+6,500
+40% +$75.1K ﹤0.01% 647
2015
Q2 		$229K Hold
16,400
– – ﹤0.01% 541
2015
Q1 		$394K Buy
+16,400
New +$369K ﹤0.01% 424

Other funds holding DRNA

CAM
Close Asset Management London, United Kingdom $3.76B AUM 40.74% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s DRNA Position: Q4 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 167,538 shares — an estimated $3.38M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in DRNA in Q1 2015 and held it in 19 quarters. The position peaked at $6.92M in Q2 2020. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 167,538 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $3.38M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2015 and held it in 19 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Dicerna Pharmaceuticals, Inc. position peaked at $6.92M in Q2 2020.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2021, filed 10 Feb 2022.